FAST NEWS: Beigene stock falls after Novartis terminates partnership
The latest: Cancer drug maker BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) announced Tuesday that Novartis (NOVN.SWX) will relinquish its rights to co-develop, produce and commercialize BeiGene’s esophagus cancer drug tislelizumab. Looking up: Novartis will provide…
Heated market for dueling blood cancer drugs lands BeiGene in court
The Chinese drug maker was sued by U.S. rival AbbVie over alleged patent infringement involving a key product for both companies Key Takeaways: A unit of AbbVie has sued BeiGene…
BeiGene goes for global growth with sales and R&D push
The maker of cancer drugs is ploughing most of its rising revenues into research and sales, as it prioritizes expansion over profits for now Key Takeaways: BeiGene’s revenue in the…
FAST NEWS: BeiGene Loss Narrows on Brisk Sales for Core Products
The latest: Cancer drug maker BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) announced Monday its revenue rose 20.4% last year to $1.42 billion, thanks to big increases from its two core products,…
Recent Articles
RELATED ARTICLES
-
Heated market for dueling blood cancer drugs lands BeiGene in court
BGNE.US 6160.HK
-
BeiGene goes for global growth with sales and R&D push
BGNE.US 6160.HK
-
Sales success comes with side effects for drug maker BeiGene
BGNE.US 6160.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
-
Adlai Nortye dives in Nasdaq debut, as key product faces hurdles
ANL.US
-
Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?
1877.HK 688180.SHG
